Does CANAGLIFLOZIN Cause Stent placement? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Stent placement have been filed in association with CANAGLIFLOZIN (INVOKANA). This represents 0.0% of all adverse event reports for CANAGLIFLOZIN.
5
Reports of Stent placement with CANAGLIFLOZIN
0.0%
of all CANAGLIFLOZIN reports
0
Deaths
1
Hospitalizations
How Dangerous Is Stent placement From CANAGLIFLOZIN?
Of the 5 reports, 1 (20.0%) required hospitalization.
Is Stent placement Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CANAGLIFLOZIN. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does CANAGLIFLOZIN Cause?
Diabetic ketoacidosis (3,413)
Toe amputation (2,193)
Osteomyelitis (2,146)
Acute kidney injury (1,853)
Fungal infection (1,385)
Gangrene (1,081)
Weight decreased (1,014)
Cellulitis (1,007)
Urinary tract infection (920)
Diabetic foot infection (832)
What Other Drugs Cause Stent placement?
RANOLAZINE (593)
EVOLOCUMAB (244)
ADALIMUMAB (227)
ROSIGLITAZONE (196)
ETANERCEPT (174)
CLOPIDOGREL BISULFATE (167)
RIVAROXABAN (122)
ASPIRIN (118)
APIXABAN (116)
MACITENTAN (108)
Which CANAGLIFLOZIN Alternatives Have Lower Stent placement Risk?
CANAGLIFLOZIN vs CANAGLIFLOZIN\METFORMIN
CANAGLIFLOZIN vs CANAKINUMAB
CANAGLIFLOZIN vs CANDESARTAN
CANAGLIFLOZIN vs CANDESARTAN CILEXETIL
CANAGLIFLOZIN vs CANDESARTAN CILEXETIL\HYDROCHLOROTHIAZIDE